CU20120063A7 - A METHOD FOR OBTAINING REPROGRAMED DAILY CELLS - Google Patents

A METHOD FOR OBTAINING REPROGRAMED DAILY CELLS

Info

Publication number
CU20120063A7
CU20120063A7 CU2012000063A CU20120063A CU20120063A7 CU 20120063 A7 CU20120063 A7 CU 20120063A7 CU 2012000063 A CU2012000063 A CU 2012000063A CU 20120063 A CU20120063 A CU 20120063A CU 20120063 A7 CU20120063 A7 CU 20120063A7
Authority
CU
Cuba
Prior art keywords
cells
patient
obtaining
compromised
transdifferentiated
Prior art date
Application number
CU2012000063A
Other languages
Spanish (es)
Other versions
CU24006B1 (en
Inventor
Ilham Mohamed Saleh Saeed Abuljadayel
Original Assignee
Tristem Trading Cyprus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tristem Trading Cyprus Ltd filed Critical Tristem Trading Cyprus Ltd
Publication of CU20120063A7 publication Critical patent/CU20120063A7/en
Publication of CU24006B1 publication Critical patent/CU24006B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a un método para la obtención de células dianas reprogramadas que pueden ser útiles para tratar diversas enfermedades, trastornos o afecciones en un paciente, mediante la utilización de células reprogramadas, como por ejemplo células retrodiferenciadas, transdiferenciadas o rediferenciadas. El método comprende obtener células comprometidas del paciente, retrodiferenciar las células comprometidas para obtener células diana retrodiferenciadas, y administrar las células retrodiferenciadas al paciente. En determinadas realizaciones, el método comprende obtener células comprometidas del paciente, transdiferenciar las células comprometidas para obtener células diana transdiferenciadas, y administrar las células diana transdiferenciadas al paciente. Las células diana retrodiferenciadas o transdiferenciadas reparan o reponen los tejidos o células en el paciente.The present invention relates to a method for obtaining reprogrammed target cells that can be useful for treating various diseases, disorders or conditions in a patient, by using reprogrammed cells, such as, for example, backdifferentiated, transdifferentiated or redifferentiated cells. The method comprises obtaining compromised cells from the patient, retrodifferentiating the compromised cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining compromised cells from the patient, transdifferentiating the compromised cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. Retrodifferentiated or transdifferentiated target cells repair or replenish tissues or cells in the patient.

CU2012000063A 2009-10-19 2012-04-19 A METHOD FOR OBTAINING REPROGRAMED DAILY CELLS CU24006B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/051396 WO2011048350A1 (en) 2009-10-19 2009-10-19 Treatment using reprogrammed mature adult cells

Publications (2)

Publication Number Publication Date
CU20120063A7 true CU20120063A7 (en) 2012-10-15
CU24006B1 CU24006B1 (en) 2014-06-27

Family

ID=42199514

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000063A CU24006B1 (en) 2009-10-19 2012-04-19 A METHOD FOR OBTAINING REPROGRAMED DAILY CELLS

Country Status (16)

Country Link
EP (1) EP2490702A1 (en)
JP (1) JP6073135B2 (en)
KR (1) KR101766203B1 (en)
CN (1) CN102647989A (en)
AU (1) AU2009354350B2 (en)
CA (1) CA2781522A1 (en)
CH (1) CH704227B1 (en)
CU (1) CU24006B1 (en)
IL (1) IL218902A (en)
MA (1) MA33740B1 (en)
MX (1) MX2012004522A (en)
RU (1) RU2635317C2 (en)
TN (1) TN2012000157A1 (en)
UA (1) UA109265C2 (en)
WO (1) WO2011048350A1 (en)
ZA (1) ZA201202664B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296595A1 (en) * 2014-09-18 2017-10-19 North Carolina State University Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
JP6113133B2 (en) 2014-11-06 2017-04-12 日本メナード化粧品株式会社 Stem cell undifferentiated state maintenance agent and growth promoter
IL300420B1 (en) 2015-10-16 2024-05-01 Univ Columbia Compositions and methods for inhibition of lineage specific antigens
CN107114355A (en) * 2016-08-01 2017-09-01 北京世纪劲得生物技术有限公司 A kind of fat cell protection liquid and preparation method thereof
CN110662554A (en) * 2017-02-28 2020-01-07 Vor生物制药股份有限公司 Compositions and methods for inhibiting lineage specific proteins
CN109731012A (en) * 2017-10-30 2019-05-10 邹兆中 It improves biological immune and treats the active method of active principle
CN109706119B (en) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 Culture system and method for expanding hematopoietic stem cells and application thereof
SG11202101994XA (en) 2018-08-28 2021-03-30 Vor Biopharma Inc Genetically engineered hematopoietic stem cells and uses thereof
KR20200025210A (en) * 2018-08-29 2020-03-10 주식회사 스템모어 Composition for culturing dermal papilla cells and the method for culturing dermal papilla cells using the same
WO2021240204A1 (en) * 2020-05-23 2021-12-02 Pakravan Nafiseh Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy
CN114231481B (en) * 2021-12-21 2023-07-18 中国人民解放军总医院 Chemical induction method for taking reprogramming Cheng Zhenpi fibroblast as endothelial progenitor cell
WO2023217126A1 (en) * 2022-05-10 2023-11-16 上海赛立维生物科技有限公司 Renal epithelial precursor-like cell, and preparation method therefor, preparation thereof and use thereof
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
WO1996035224A1 (en) * 1995-05-02 1996-11-07 Philips Electronics N.V. Colour cathode ray tube
US20050037490A1 (en) * 1999-10-29 2005-02-17 Lawrence Rosenberg Medium for preparing dedifferentiated cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
WO2006014642A1 (en) * 2004-07-22 2006-02-09 Five Prime Therapeutics, Inc. Method of producing autologous embryonic stem cells
KR20110134939A (en) * 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 Induced pluripotent stem cells

Also Published As

Publication number Publication date
JP6073135B2 (en) 2017-02-01
EP2490702A1 (en) 2012-08-29
IL218902A0 (en) 2012-06-28
RU2635317C2 (en) 2017-11-10
KR101766203B1 (en) 2017-08-08
TN2012000157A1 (en) 2013-12-12
AU2009354350B2 (en) 2015-09-03
RU2012120713A (en) 2013-11-27
AU2009354350A1 (en) 2012-04-19
CH704227B1 (en) 2015-05-15
KR20120099686A (en) 2012-09-11
CN102647989A (en) 2012-08-22
UA109265C2 (en) 2015-08-10
WO2011048350A1 (en) 2011-04-28
CA2781522A1 (en) 2011-04-28
JP2013508343A (en) 2013-03-07
IL218902A (en) 2017-06-29
MX2012004522A (en) 2012-05-08
CU24006B1 (en) 2014-06-27
MA33740B1 (en) 2012-11-01
ZA201202664B (en) 2013-02-27

Similar Documents

Publication Publication Date Title
CU20120063A7 (en) A METHOD FOR OBTAINING REPROGRAMED DAILY CELLS
CO6511283A2 (en) USEFUL REPLACED PRIMIDINES IN THE TREATMENT OF DISEASES SUCH AS CANCER
BR122019002291B8 (en) process for the production of methyl-4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinylcarbamate and process for the production of methyl -{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate
UY33199A (en) 5-ALQUINIL-PYRIMIDINS.
UY32958A (en) GLICOSIDE DERIVATIVES AND USES OF THE SAME.
ECSP10010475A (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS
BR112014014376A2 (en) substrate with a structured surface and methods for its production, and methods for determining its wetting properties
BR112014005103A2 (en) organic compositions for treating diseases associated with hsf1
ECSP12011830A (en) NEW COMPOUNDS.
ECSP11010816A (en) New Compounds
UY32240A (en) NEW 2,4-DIAMINOPIRIMIDINAS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, COMPOSITIONS CONTAINING THEM AND APPLICATIONS.
UY32009A (en) 5-ALQUINIL-PYRIMIDINS
ECSP12012230A (en) ROBO1-FC FUSION PROTEIN AND ITS USE IN TUMOR TREATMENT
UY32748A (en) 2-CARBOXAMIDA-CICLOAMINO-UREAS
CR20130094A (en) ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND EYE HYPERTENSION
UY32747A (en) 2-CARBOXAMIDA-CICLOAMINO-SUBSTITUTED UREAS
CO6290768A2 (en) TIAZOLIL-DIHIDRO-INDAZOLES
CO6460762A2 (en) 5-ALQUINIL-PIRIDINAS
BR112012019920A2 (en) pyridazine derivatives useful as cannabinoid-2 agonists.
CR20110023A (en) NIFURTIMOX FOR THE TREATMENT OF DISEASES CAUSED BY TRICHOMONADIDA
BR112015017830A2 (en) processes and means to increase stress tolerance and biomass in plants
UY32385A (en) AMIDAS OF REPLACED PIRAZINONA
UY32878A (en) COMPOSITIONS FOR LEATHER FINISHING THAT INCLUDE DERIVATIVES OF DIOXOLANE
UY32186A (en) TREATMENT USING REPROGRAMED MATURE ADULT CELLS
CO6460760A2 (en) TIA-TRIAZA-CICLOPENTAZULENOS

Legal Events

Date Code Title Description
FG Grant of patent